HomeBUSINESS
BUSINESS

Daiichi Sankyo to Consider Further Development of DS-8201 for HER2 Low-Expressing Breast Cancer
(Dec.11.2017)

Daiichi Sankyo’s investigational HER2-targeting antibody drug conjugate (ADC) DS-8201 has demonstrated its efficacy in patients with HER2 low-expressing breast cancer in a PI clinical study conducted in Japan and the US, the company recently said ...
(LOG IN FOR FULL STORY)

News Calendar